Zobrazeno 1 - 10 of 18 pro vyhledávání: '"M. E. Schram"'
1
Akademický článek
Can serum biomarkers predict the outcome of systemic immunosuppressive therapy in adult atopic dermatitis patients?
Autor: G. Hurault, E. Roekevisch, M. E. Schram, K. Szegedi, S. Kezic, M. A. Middelkamp‐Hup, P. I. Spuls, R. J. Tanaka
Publikováno v: Skin Health and Disease, Vol 2, Iss 1, Pp n/a-n/a (2022)
Abstract Background Atopic dermatitis (AD or eczema) is a most common chronic skin disease. Designing personalised treatment strategies for AD based on patient stratification is of high clinical relevance, given a considerable variation in the clinic
Externí odkaz: https://doaj.org/article/9f06ff76519f475a85e1382e38056bc3
Zobrazit plný text záznamu
2
Can serum biomarkers predict the outcome of systemic therapy for atopic dermatitis?
Autor: M. E. Schram, Reiko J. Tanaka, Evelien Roekevisch, Phyllis I. Spuls, Guillem Hurault, M.A. Middelkamp‐Hup, Sanja Kezic, Krisztina Szegedi
SUMMARYBackgroundAtopic dermatitis (AD or eczema) is a most common chronic skin disease. Designing personalised treatment strategies for AD based on patient stratification, rather than the “one-size-fits-all” treatments, is of high clinical relev
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::05e77b967b2faefd81070755a302ddf3
https://doi.org/10.1101/2020.12.02.20242404
Zobrazit plný text záznamu
3
Effect of immunosuppressive treatment on biomarkers in adult atopic dermatitis patients
Autor: Jan D. Bos, Evelien Roekevisch, Krisztina Szegedi, Sanja Kezic, M. E. Schram, Rosalie M. Luiten, Pieter C.M. Res, Mariska M.G. Leeflang, Ph.I. Spuls, D.P. Hack, M.A. Middelkamp‐Hup
Publikováno v: Journal of the European Academy of Dermatology and Venereology, 34(7), 1545-1554. Wiley-Blackwell
Journal of the European Academy of Dermatology and Venereology
Background Biomarkers to objectively measure disease severity and predict therapeutic responses are needed in atopic dermatitis (AD). Objective Primary aim: To identify biomarkers reflecting therapeutic response in patients with AD treated systemical
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d738d3951e2df5e633e277fcaaed199c
https://pure.amc.nl/en/publications/effect-of-immunosuppressive-treatment-on-biomarkers-in-adult-atopic-dermatitis-patients(8cea7ae2-d207-4256-a81a-fc62238d2ef6).html
Zobrazit plný text záznamu
5
In vivo confocal microscopy of basal cell carcinoma: a systematic review of diagnostic accuracy
Autor: Jacqueline Limpens, D.J. Kadouch, M. E. Schram, M.A. de Rie, Ph.I. Spuls, Mariska M.G. Leeflang
Publikováno v: Journal of the European Academy of Dermatology and Venereology. 29(10):1890-1897
Basal cell carcinoma (BCC) is the most prevalent type of skin cancer. Histologic analysis of punch biopsy or direct excision specimen is used to confirm clinical diagnosis. In vivo reflectance confocal microscopy (RCM) is a non-invasive imaging modal
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75bc29ed68d6d694563692e19cc9c30d
https://doi.org/10.1111/jdv.13224
Zobrazit plný text záznamu
6
Patients with atopic dermatitis with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment
Autor: Sanja Kezic, Ph.I. Spuls, W.H. Irwin McLean, Jan D. Bos, Linda E. Campbell, M. M. G. Leeflang, M. E. Schram, M.A. Middelkamp‐Hup, Evelien Roekevisch
Publikováno v: British journal of dermatology, 177(6), 1745-1746. Wiley-Blackwell
Filaggrin (FLG) mutations are a strong risk factor to develop atopic dermatitis (AD). However, the relationship between FLG mutations and treatment outcome in AD has not been thoroughly studied. To investigate whether FLG mutations influence immunosu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52ef88d5e1e59b07fab16870a2c30baa
https://pubmed.ncbi.nlm.nih.gov/27864930
Zobrazit plný text záznamu
7
EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference
Autor: Ph.I. Spuls, Jan D. Bos, M. E. Schram, Mariska M.G. Leeflang, Jochen Schmitt, R. Lindeboom
Publikováno v: Allergy. 67:99-106
To cite this article: Schram ME, Spuls PI, Leeflang MMG, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy 2012; 67: 99–106. Abstract Background:
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4bdf07761670def39ee813a757f035f8
https://doi.org/10.1111/j.1398-9995.2011.02719.x
Zobrazit plný text záznamu
8
Off-label Use of Azathioprine in Dermatology A Systematic Review
Autor: Jan G. van der Schroeff, Phyllis I. Spuls, Cathelijne M. J. M. Bik, M. E. Schram, Jannes J. E. van Everdingen, Rinke J. Borgonjen
Publikováno v: Archives of dermatology. 147(4):474-488
Objective: To summarize evidence regarding the effectiveness, efficacy, and safety of off-label azathioprine use in dermatology. Data Sources: We searched the MEDLINE (1950-2009), EMBASE (1980-2009), and CENTRAL (1996-2009) databases on October 9, 20
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cb812d4aace729e62b309744884db66
https://doi.org/10.1001/archdermatol.2011.79
Zobrazit plný text záznamu
9
Off-label use of efalizumab in dermatology
Autor: M. E. Schram, Phyllis I. Spuls, Jan D. Bos
Publikováno v: Expert Review of Dermatology. 5:535-547
In reaction to the marketing suspension recommended by the European Medicines Agency, Genentech announced the voluntary withdrawal of efalizumab. Since June 8, 2009, efalizumab has been unavailable. Despite the fact that the use of efalizumab is now
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4dc90bbaccd5149361225a6778923821
https://doi.org/10.1586/edm.10.44
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje